Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

ST. LOUIS (InvestigateTV) — At this Missouri high school, students are learning real-world experience each day. Behind the desk of the COPILOT program, electronic devices used by staff members are ...

Great leadership doesn’t just happen in boardrooms or business settings. From little league coaching and community initiatives to family moments and encounters with service providers, powerful ...

Beacon Software, the AI holding company building the permanent home for essential vertical software and services, today announced a $250 million Series B financing led by General Catalyst, Lightspeed ...